Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1847 1
1885 1
1906 1
1910 1
1946 2
1948 1
1949 1
1950 1
1952 3
1953 5
1954 8
1955 4
1956 3
1957 2
1958 4
1959 6
1960 4
1961 7
1962 1
1963 6
1964 13
1965 13
1966 14
1967 24
1968 22
1969 39
1970 34
1971 47
1972 42
1973 47
1974 49
1975 60
1976 71
1977 64
1978 63
1979 60
1980 96
1981 58
1982 86
1983 91
1984 98
1985 86
1986 87
1987 88
1988 77
1989 110
1990 133
1991 126
1992 87
1993 114
1994 104
1995 98
1996 113
1997 72
1998 101
1999 99
2000 114
2001 127
2002 108
2003 136
2004 160
2005 191
2006 190
2007 163
2008 204
2009 218
2010 222
2011 266
2012 259
2013 291
2014 319
2015 287
2016 326
2017 335
2018 344
2019 362
2020 375
2021 388
2022 373
2023 384
2024 191

Text availability

Article attribute

Article type

Publication date

Search Results

8,147 results

Results by year

Filters applied: . Clear all
Page 1
Oxalate homeostasis.
Ermer T, Nazzal L, Tio MC, Waikar S, Aronson PS, Knauf F. Ermer T, et al. Nat Rev Nephrol. 2023 Feb;19(2):123-138. doi: 10.1038/s41581-022-00643-3. Epub 2022 Nov 3. Nat Rev Nephrol. 2023. PMID: 36329260 Free PMC article. Review.
Novel studies have shed light on the essential roles of metabolic pathways, the microbiome, epithelial oxalate transporters, and adequate oxalate excretion to maintain oxalate homeostasis. ...Beyond well-known interventions (such as dietary modifications), no …
Novel studies have shed light on the essential roles of metabolic pathways, the microbiome, epithelial oxalate transporters, and adeq …
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
The primary end point was the percent change in 24-hour urinary oxalate excretion from baseline to month 6 (mean percent change across months 3 through 6). Secondary end points included the percent change in the plasma oxalate level from baseline to month 6 (mean pe …
The primary end point was the percent change in 24-hour urinary oxalate excretion from baseline to month 6 (mean percent change acros …
Ferrostatin-1 alleviates oxalate-induced renal tubular epithelial cell injury, fibrosis and calcium oxalate stone formation by inhibiting ferroptosis.
Xie J, Ye Z, Li L, Xia Y, Yuan R, Ruan Y, Zhou X. Xie J, et al. Mol Med Rep. 2022 Aug;26(2):256. doi: 10.3892/mmr.2022.12772. Epub 2022 Jun 15. Mol Med Rep. 2022. PMID: 35703358 Free PMC article.
The present study aimed to evaluate the role and mechanism of ferrostatin-1 (Fer-1) in oxalate (Ox)-induced renal tubular epithelial cell injury, fibrosis, and calcium oxalate (CaOx) stone formation. ...Renal tissue damage, apoptosis of renal tubular epithelial cell …
The present study aimed to evaluate the role and mechanism of ferrostatin-1 (Fer-1) in oxalate (Ox)-induced renal tubular epithelial …
Secondary oxalate nephropathy and kidney transplantation.
Aziz F, Jorgenson M, Garg N. Aziz F, et al. Curr Opin Organ Transplant. 2023 Feb 1;28(1):15-21. doi: 10.1097/MOT.0000000000001035. Epub 2022 Nov 7. Curr Opin Organ Transplant. 2023. PMID: 36342385 Review.
Though treatment options for secondary hyperoxaluria are limited, it is crucial to identify patients at increased risk of oxalate nephropathy after the transplant. ...This review will discuss the incidence, risk factors, prevention, and management of oxalate …
Though treatment options for secondary hyperoxaluria are limited, it is crucial to identify patients at increased risk of oxalate …
Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion.
Crivelli JJ, Mitchell T, Knight J, Wood KD, Assimos DG, Holmes RP, Fargue S. Crivelli JJ, et al. Nutrients. 2020 Dec 28;13(1):62. doi: 10.3390/nu13010062. Nutrients. 2020. PMID: 33379176 Free PMC article. Review.
Kidney stone disease is increasing in prevalence, and the most common stone composition is calcium oxalate. Dietary oxalate intake and endogenous production of oxalate are important in the pathophysiology of calcium oxalate stone disease. ...Net gastro …
Kidney stone disease is increasing in prevalence, and the most common stone composition is calcium oxalate. Dietary oxalate in …
Improving Treatment Options for Primary Hyperoxaluria.
Hoppe B, Martin-Higueras C. Hoppe B, et al. Drugs. 2022 Jul;82(10):1077-1094. doi: 10.1007/s40265-022-01735-x. Epub 2022 Jul 2. Drugs. 2022. PMID: 35779234 Free PMC article. Review.
Similar to vitamin B(6) treatment, where both RNA interference urinary oxalate excretion can be (near) normalized and plasma oxalate decreases, however, urinary and plasma glycolate increases with lumasiran treatment. Future treatment possibilit …
Similar to vitamin B(6) treatment, where both RNA interference urinary oxalate excretion can be (near) normalized and plasma …
Tea oxalate.
Massey LK. Massey LK. Nutr Rev. 2000 Mar;58(3 Pt 1):88-9. doi: 10.1111/j.1753-4887.2000.tb01845.x. Nutr Rev. 2000. PMID: 10812924 No abstract available.
Future treatments for hyperoxaluria.
Burns Z, Knight J, Fargue S, Holmes R, Assimos D, Wood K. Burns Z, et al. Curr Opin Urol. 2020 Mar;30(2):171-176. doi: 10.1097/MOU.0000000000000709. Curr Opin Urol. 2020. PMID: 31895888 Free PMC article. Review.
PURPOSE OF REVIEW: The review of potential therapies in the treatment of hyperoxaluria is timely, given the current excitement with clinical trials and the mounting evidence of the importance of oxalate in both kidney stone and chronic kidney disease. RECENT FINDING …
PURPOSE OF REVIEW: The review of potential therapies in the treatment of hyperoxaluria is timely, given the current excitement with c …
Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.
Holmes RP, Knight J, Assimos DG. Holmes RP, et al. Urolithiasis. 2016 Feb;44(1):27-32. doi: 10.1007/s00240-015-0839-4. Epub 2015 Nov 27. Urolithiasis. 2016. PMID: 26614109 Free PMC article. Review.
Dietary modifications should be considered as a first line approach in the treatment of idiopathic calcium oxalate nephrolithiasis. The amounts of oxalate and calcium consumed in the diet are significant factors in the development of the disease due to their …
Dietary modifications should be considered as a first line approach in the treatment of idiopathic calcium oxalate nephrolithi …
Zn(2+) regulates human oxalate metabolism by manipulating oxalate decarboxylase to treat calcium oxalate stones.
Wu F, Cheng Y, Zhou J, Liu X, Lin R, Xiang S, Liu Z, Wang C. Wu F, et al. Int J Biol Macromol. 2023 Apr 15;234:123320. doi: 10.1016/j.ijbiomac.2023.123320. Epub 2023 Jan 19. Int J Biol Macromol. 2023. PMID: 36682657
A high concentration of oxalate is associated with an increased risk of kidney calcium oxalate (CaOx) stones, and the degradation of exogenous oxalate mostly depends on oxalate-degrading enzymes from the intestinal microbiome. We found that zinc glucon …
A high concentration of oxalate is associated with an increased risk of kidney calcium oxalate (CaOx) stones, and the degradat …
8,147 results